Role of the JAK/STAT signaling pathway in regulation of innate immunity in neuroinflammatory diseases

Clinical Immunology

Volumn 189, Issue , 2018, Pages 4-13

  Yan, Zhaoqi ^a   Gibson, Sara A ^a   Buckley, Jessica A ^a   Qin, Hongwei ^a   Benveniste, Etty N ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Innate immunity; JAK STAT pathway; Multiple sclerosis; Parkinson's disease

Indexed keywords

JANUS KINASE; JANUS KINASE INHIBITOR; PROTEIN INHIBITOR; STAT PROTEIN;

ARTICLE; ASTROCYTE; CELL INFILTRATION; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; HUMAN; IMMUNOCOMPETENT CELL; INNATE IMMUNITY; JAK-STAT SIGNALING; MACROPHAGE; MICROGLIA; MULTIPLE SCLEROSIS; NEUTROPHIL; NONHUMAN; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN FUNCTION; BIOLOGICAL MODEL; IMMUNOLOGY; METABOLISM; SIGNAL TRANSDUCTION;

HUMANS; IMMUNITY, INNATE; JANUS KINASES; MACROPHAGES; MICROGLIA; MODELS, IMMUNOLOGICAL; MULTIPLE SCLEROSIS; PARKINSON DISEASE; SIGNAL TRANSDUCTION; STAT TRANSCRIPTION FACTORS;

EID: 85002410287     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2016.09.014     Document Type: Article

References (151)

1. O'Shea, J.J., Gadina, M., Kanno, Y., Cytokine signaling: birth of a pathway. J. Immunol. 187 (2011), 5475–5478.
2. O'Shea, J.J., Plenge, R., JAK and STAT signaling molecules in immunoregulation and immune-mediated disease. Immunity 36 (2012), 542–550.
3. Ransohoff, R.M., Brown, M.A., Innate immunity in the central nervous system. J. Clin. Invest. 122 (2012), 1164–1171.
4. Louveau, A., Harris, T.H., Kipnis, J., Revisiting the mechanisms of CNS immune privilege. Trends Immunol. 36 (2015), 569–577.
5. Nimmerjahn, A., Kirchhoff, F., Helmchen, F., Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo. Science 308 (2005), 1314–1318.
6. Davalos, D., Grutzendler, J., Yang, G., Kim, J.V., Zuo, Y., Jung, S., Littman, D.R., Dustin, M.L., Gan, W.B., ATP mediates rapid microglial response to local brain injury in vivo. Nat. Neurosci. 8 (2005), 752–758.
7. Nayak, D., Roth, T.L., McGavern, D.B., Microglia development and function. Annu. Rev. Immunol. 32 (2014), 367–402.
8. Khakh, B.S., Sofroniew, M.V., Diversity of astrocyte functions and phenotypes in neural circuits. Nat. Neurosci. 18 (2015), 942–952.
9. Tanuma, N., Sakuma, H., Sasaki, A., Matsumoto, Y., Chemokine expression by astrocytes plays a role in microglia/macrophage activation and subsequent neurodegeneration in secondary progressive multiple sclerosis. Acta Neuropathol. 112 (2006), 195–204.
10. Farina, C., Aloisi, F., Meinl, E., Astrocytes are active players in cerebral innate immunity. Trends Immunol. 28 (2007), 138–145.
11. Mayo, L., Trauger, S.A., Blain, M., Nadeau, M., Patel, B., Alvarez, J.I., Mascanfroni, I.D., Yeste, A., Kivisakk, P., Kallas, K., Ellezam, B., Bakshi, R., Prat, A., Antel, J.P., Weiner, H.L., Quintana, F.J., Regulation of astrocyte activation by glycolipids drives chronic CNS inflammation. Nat. Med. 20 (2014), 1147–1156.
12. Goldstein, E.Z., Church, J.S., Hesp, Z.C., Popovich, P.G., McTigue, D.M., A silver lining of neuroinflammation: beneficial effects on myelination. Exp. Neurol. 283 (2016), 550–559.
13. Gaesser, J.M., Fyffe-Maricich, S.L., Intracellular signaling pathway regulation of myelination and remyelination in the CNS. Exp. Neurol. 283 (2016), 501–511.
14. Lin, W., Kemper, A., Dupree, J.L., Harding, H.P., Ron, D., Popko, B., Interferon-γ inhibits central nervous system remyelination through a process modulated by endoplasmic reticulum stress. Brain 129 (2006), 1306–1318.
15. Hussien, Y., Podojil, J.R., Robinson, A.P., Lee, A.S., Miller, S.D., Popko, B., ER chaperone BiP/GRP78 is required for myelinating cell survival and provides protection during experimental autoimmune encephalomyelitis. J. Neurosci. 35 (2015), 15921–15933.
16. Church, J.S., Kigerl, K.A., Lerch, J.K., Popovich, P.G., McTigue, D.M., TLR4 deficiency impairs oligodendrocyte formation in the injured spinal cord. J. Neurosci. 36 (2016), 6352–6364.
17. Moore, C.S., Cui, Q.L., Warsi, N.M., Durafourt, B.A., Zorko, N., Owen, D.R., Antel, J.P., Bar-Or, A., Direct and indirect effects of immune and central nervous system-resident cells on human oligodendrocyte progenitor cell differentiation. J. Immunol. 194 (2015), 761–772.
18. Traka, M., Podojil, J.R., McCarthy, D.P., Miller, S.D., Popko, B., Oligodendrocyte death results in immune-mediated CNS demyelination. Nat. Neurosci. 19 (2016), 65–74.
19. Ousman, S.S., Kubes, P., Immune surveillance in the central nervous system. Nat. Neurosci. 15 (2012), 1096–1101.
20. Louveau, A., Smirnov, I., Keyes, T.J., Eccles, J.D., Rouhani, S.J., Peske, J.D., Derecki, N.C., Castle, D., Mandell, J.W., Lee, K.S., Harris, T.H., Kipnis, J., Structural and functional features of central nervous system lymphatic vessels. Nature 523 (2015), 337–341.
21. Aspelund, A., Antila, S., Proulx, S.T., Karlsen, T.V., Karaman, S., Detmar, M., Wiig, H., Alitalo, K., A dural lymphatic vascular system that drains brain interstitial fluid and macromolecules. J. Exp. Med. 212 (2015), 991–999.
22. Li, J., Gran, B., Zhang, G.X., Ventura, E.S., Siglienti, I., Rostami, A., Kamoun, M., Differential expression and regulation of IL-23 and IL-12 subunits and receptors in adult mouse microglia. J. Neurol. Sci. 215 (2003), 95–103.
23. Lee, E.J., Woo, M.S., Moon, P.G., Baek, M.C., Choi, I.Y., Kim, W.K., Junn, E., Kim, H.S., Alpha-synuclein activates microglia by inducing the expressions of matrix metalloproteinases and the subsequent activation of protease-activated receptor-1. J. Immunol. 185 (2010), 615–623.
24. Noubade, R., Wong, K., Ota, N., Rutz, S., Eidenschenk, C., Valdez, P.A., Ding, J., Peng, I., Sebrell, A., Caplazi, P., DeVoss, J., Soriano, R.H., Sai, T., Lu, R., Modrusan, Z., Hackney, J., Ouyang, W., NRROS negatively regulates reactive oxygen species during host defence and autoimmunity. Nature 509 (2014), 235–239.
25. Herz, J., Johnson, K.R., McGavern, D.B., Therapeutic antiviral T cells noncytopathically clear persistently infected microglia after conversion into antigen-presenting cells. J. Exp. Med. 212 (2015), 1153–1169.
26. Mack, C.L., Vanderlugt-Castaneda, C.L., Neville, K.L., Miller, S.D., Microglia are activated to become competent antigen presenting and effector cells in the inflammatory environment of the Theiler's virus model of multiple sclerosis. J. Neuroimmunol. 144 (2003), 68–79.
27. Harms, A.S., Cao, S., Rowse, A.L., Thome, A.D., Li, X., Mangieri, L.R., Cron, R.Q., Shacka, J.J., Raman, C., Standaert, D.G., MHCII is required for α-synuclein-induced activation of microglia, CD4 T cell proliferation, and dopaminergic neurodegeneration. J. Neurosci. 33 (2013), 9592–9600.
28. McGeer, P.L., Itagaki, S., Boyes, B.E., McGeer, E.G., Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology 38 (1988), 1285–1291.
29. Gobin, S.J.P., Montagne, L., Van Zutphen, M., Van Der Valk, P., Van Den Elsen, P.J., De Groot, C.J.A., Upregulation of transcription factors controlling MHC expression in multiple sclerosis lesions. Glia 36 (2001), 68–77.
30. Fischer, H.G., Bonifas, U., Reichmann, G., Phenotype and functions of brain dendritic cells emerging during chronic infection of mice with Toxoplasma gondii. J. Immunol. 164 (2000), 4826–4834.
31. McMahon, E.J., Bailey, S.L., Castenada, C.V., Waldner, H., Miller, S.D., Epitope spreading initiates in the CNS in two mouse models of multiple sclerosis. Nat. Med. 11 (2005), 335–339.
32. Mantovani, A., Cassatella, M.A., Costantini, C., Jaillon, S., Neutrophils in the activation and regulation of innate and adaptive immunity. Nat. Rev. Immunol. 11 (2011), 519–531.
33. Pelletier, M., Maggi, L., Micheletti, A., Lazzeri, E., Tamassia, N., Costantini, C., Cosmi, L., Lunardi, C., Annunziato, F., Romagnani, S., Cassatella, M.A., Evidence for a cross-talk between human neutrophils and Th17 cells. Blood 115 (2010), 335–343.
34. Yamasaki, R., Lu, H., Butovsky, O., Ohno, N., Rietsch, A.M., Cialic, R., Wu, P.M., Doykan, C.E., Lin, J., Cotleur, A.C., Kidd, G., Zorlu, M.M., Sun, N., Hu, W., Liu, L., Lee, J.-C., Taylor, S.E., Uehlein, L., Dixon, D., Gu, J., Floruta, C.M., Zhu, M., Charo, I.F., Weiner, H.L., Ransohoff, R.M., Differential roles of microglia and monocytes in the inflamed central nervous system. J. Exp. Med. 211 (2014), 1533–1549.
35. Liu, Y., Holdbrooks, A.T., Meares, G.P., Buckley, J.A., Benveniste, E.N., Qin, H., Preferential recruitment of neutrophils into the cerebellum and brainstem contributes to the atypical experimental autoimmune encephalomyelitis phenotype. J. Immunol. 195 (2015), 841–852.
36. Steinbach, K., Piedavent, M., Bauer, S., Neumann, J.T., Friese, M.A., Neutrophils amplify autoimmune central nervous system infiltrates by maturing local APCs. J. Immunol. 191 (2013), 4531–4539.
37. Hao, J., Liu, R., Piao, W., Zhou, Q., Vollmer, T.L., Campagnolo, D.I., Xiang, R., La Cava, A., Van Kaer, L., Shi, F.D., Central nervous system (CNS)-resident natural killer cells suppress Th17 responses and CNS autoimmune pathology. J. Exp. Med. 207 (2010), 1907–1921.
38. Winkler-Pickett, R., Young, H.A., Cherry, J.M., Diehl, J., Wine, J., Back, T., Bere, W.E., Mason, A.T., Ortaldo, J.R., In vivo regulation of experimental autoimmune encephalomyelitis by NK cells: alteration of primary adaptive responses. J. Immunol. 180 (2008), 4495–4506.
39. Poli, A., Kmiecik, J., Domingues, O., Hentges, F., Blery, M., Chekenya, M., Boucraut, J., Zimmer, J., NK cells in central nervous system disorders. J. Immunol. 190 (2013), 5355–5362.
40. Benveniste, E.N., Liu, Y., McFarland, B.C., Qin, H., Involvement of the Janus kinase/signal transducer and activator of transcription signaling pathway in multiple sclerosis and the animal model of experimental autoimmune encephalomyelitis. J. Interf. Cytokine Res. 34 (2014), 577–588.
41. Murray, P.J., The JAK-STAT signaling pathway: input and output integration. J. Immunol. 178 (2007), 2623–2629.
42. van Boxel-Dezaire, A.H., Rani, M.R., Stark, G.R., Complex modulation of cell type-specific signaling in response to type I interferons. Immunity 25 (2006), 361–372.
43. Baker, B.J., Akhtar, L.N., Benveniste, E.N., SOCS1 and SOCS3 in the control of CNS immunity. Trends Immunol. 30 (2009), 392–400.
44. Babon, J.J., Sabo, J.K., Zhang, J.G., Nicola, N.A., Norton, R.S., The SOCS box encodes a hierarchy of affinities for Cullin 5: implications for ubiquitin ligase formation and cytokine signalling suppression. J. Mol. Biol. 387 (2009), 162–174.
45. Yoshimura, A., Naka, T., Kubo, M., SOCS proteins, cytokine signalling and immune regulation. Nat. Rev. Immunol. 7 (2007), 454–465.
46. Dendrou, C.A., Fugger, L., Friese, M.A., Immunopathology of multiple sclerosis. Nat. Rev. Immunol. 15 (2015), 545–558.
47. Goverman, J., Autoimmune T cell responses in the central nervous system. Nat. Rev. Immunol. 9 (2009), 393–407.
48. Ortega, S.B., Kashi, V.P., Tyler, A.F., Cunnusamy, K., Mendoza, J.P., Karandikar, N.J., The disease-ameliorating function of autoregulatory CD8 T cells is mediated by targeting of encephalitogenic CD4 T cells in experimental autoimmune encephalomyelitis. J. Immunol. 191 (2013), 117–126.
49. Ray, A., Basu, S., Williams, C.B., Salzman, N.H., Dittel, B.N., A novel IL-10-independent regulatory role for B cells in suppressing autoimmunity by maintenance of regulatory T cells via GITR ligand. J. Immunol. 188 (2012), 3188–3198.
50. Ransohoff, R.M., Hafler, D.A., Lucchinetti, C.F., Multiple sclerosis-a quiet revolution. Nat. Rev. Neurol. 11 (2015), 134–142.
51. Robinson, A.P., Harp, C.T., Noronha, A., Miller, S.D., The experimental autoimmune encephalomyelitis (EAE) model of MS: utility for understanding disease pathophysiology and treatment. Handb. Clin. Neurol. 122 (2014), 173–189.
52. Jager, A., Dardalhon, V., Sobel, R.A., Bettelli, E., Kuchroo, V.K., Th1, Th17, and Th9 effector cells induce experimental autoimmune encephalomyelitis with different pathological phenotypes. J. Immunol. 183 (2009), 7169–7177.
53. Saederup, N., Cardona, A.E., Croft, K., Mizutani, M., Cotleur, A.C., Tsou, C.L., Ransohoff, R.M., Charo, I.F., Selective chemokine receptor usage by central nervous system myeloid cells in CCR2-red fluorescent protein knock-in mice. PLoS One, 5, 2010, e13693.
54. Mizutani, M., Pino, P.A., Saederup, N., Charo, I.F., Ransohoff, R.M., Cardona, A.E., The fractalkine receptor but not CCR2 is present on microglia from embryonic development throughout adulthood. J. Immunol. 188 (2012), 29–36.
55. Shaked, I., Hanna, R.N., Shaked, H., Chodaczek, G., Nowyhed, H.N., Tweet, G., Tacke, R., Basat, A.B., Mikulski, Z., Togher, S., Miller, J., Blatchley, A., Salek-Ardakani, S., Darvas, M., Kaikkonen, M.U., Thomas, G.D., Lai-Wing-Sun, S., Rezk, A., Bar-Or, A., Glass, C.K., Bandukwala, H., Hedrick, C.C., Transcription factor Nr4a1 couples sympathetic and inflammatory cues in CNS-recruited macrophages to limit neuroinflammation. Nat. Immunol. 16 (2015), 1228–1234.
56. Murray, P.J., Allen, J.E., Biswas, S.K., Fisher, E.A., Gilroy, D.W., Goerdt, S., Gordon, S., Hamilton, J.A., Ivashkiv, L.B., Lawrence, T., Locati, M., Mantovani, A., Martinez, F.O., Mege, J.L., Mosser, D.M., Natoli, G., Saeij, J.P., Schultze, J.L., Shirey, K.A., Sica, A., Suttles, J., Udalova, I., van Ginderachter, J.A., Vogel, S.N., Wynn, T.A., Macrophage activation and polarization: nomenclature and experimental guidelines. Immunity 41 (2014), 14–20.
57. Martinez, F.O., Gordon, S., The M1 and M2 paradigm of macrophage activation: time for reassessment. F1000Prime Rep. 6 (2014), 1–13.
58. O'Rourke, J.G., Bogdanik, L., Yanez, A., Lall, D., Wolf, A.J., Muhammad, A.K., Ho, R., Carmona, S., Vit, J.P., Zarrow, J., Kim, K.J., Bell, S., Harms, M.B., Miller, T.M., Dangler, C.A., Underhill, D.M., Goodridge, H.S., Lutz, C.M., Baloh, R.H., C9orf72 is required for proper macrophage and microglial function in mice. Science 351 (2016), 1324–1329.
59. Zhu, C., Herrmann, U.S., Falsig, J., Abakumova, I., Nuvolone, M., Schwarz, P., Frauenknecht, K., Rushing, E.J., Aguzzi, A., A neuroprotective role for microglia in prion diseases. J. Exp. Med. 213 (2016), 1047–1059.
60. Goldmann, T., Zeller, N., Raasch, J., Kierdorf, K., Frenzel, K., Ketscher, L., Basters, A., Staszewski, O., Brendecke, S.M., Spiess, A., Tay, T.L., Kreutz, C., Timmer, J., Mancini, G.M., Blank, T., Fritz, G., Biber, K., Lang, R., Malo, D., Merkler, D., Heikenwalder, M., Knobeloch, K.P., Prinz, M., USP18 lack in microglia causes destructive interferonopathy of the mouse brain. EMBO J. 34 (2015), 1612–1629.
61. Olah, M., Amor, S., Brouwer, N., Vinet, J., Eggen, B., Biber, K., Boddeke, H.W., Identification of a microglia phenotype supportive of remyelination. Glia 60 (2012), 306–321.
62. Waschbisch, A., Schroder, S., Schraudner, D., Sammet, L., Weksler, B., Melms, A., Pfeifenbring, S., Stadelmann, C., Schwab, S., Linker, R.A., Pivotal role for CD16 + monocytes in immune surveillance of the central nervous system. J. Immunol. 196 (2016), 1558–1567.
63. Wang, Y., Ulland, T.K., Ulrich, J.D., Song, W., Tzaferis, J.A., Hole, J.T., Yuan, P., Mahan, T.E., Shi, Y., Gilfillan, S., Cella, M., Grutzendler, J., DeMattos, R.B., Cirrito, J.R., Holtzman, D.M., Colonna, M., TREM2-mediated early microglial response limits diffusion and toxicity of amyloid plaques. J. Exp. Med. 213 (2016), 667–675.
64. Hamilton, J.A., Colony-stimulating factors in inflammation and autoimmunity. Nat. Rev. Immunol. 8 (2008), 533–544.
65. Lee, Y., Awasthi, A., Yosef, N., Quintana, F.J., Xiao, S., Peters, A., Wu, C., Kleinewietfeld, M., Kunder, S., Hafler, D.A., Sobel, R.A., Regev, A., Kuchroo, V.K., Induction and molecular signature of pathogenic T(H)17 cells. Nat. Immunol. 13 (2012), 991–999.
66. Xiao, S., Yosef, N., Yang, J., Wang, Y., Zhou, L., Zhu, C., Wu, C., Baloglu, E., Schmidt, D., Ramesh, R., Lobera, M., Sundrud, M.S., Tsai, P.Y., Xiang, Z., Wang, J., Xu, Y., Lin, X., Kretschmer, K., Rahl, P.B., Young, R.A., Zhong, Z., Hafler, D.A., Regev, A., Ghosh, S., Marson, A., Kuchroo, V.K., Small-molecule RORgammat antagonists inhibit T helper 17 cell transcriptional network by divergent mechanisms. Immunity 40 (2014), 477–489.
67. Basu, R., Hatton, R.D., Weaver, C.T., The Th17 family: flexibility follows function. Immunol. Rev. 252 (2013), 89–103.
68. Palmer, M.T., Weaver, C.T., Autoimmunity: increasing suspects in the CD4 + T cell lineup. Nat. Immunol. 11 (2010), 36–40.
69. Croxford, A.L., Lanzinger, M., Hartmann, F.J., Schreiner, B., Mair, F., Pelczar, P., Clausen, B.E., Jung, S., Greter, M., Becher, B., The cytokine GM-CSF drives the inflammatory signature of CCR2 + monocytes and licenses autoimmunity. Immunity 43 (2015), 502–514.
70. Vogel, D.Y., Vereyken, E.J., Glim, J.E., Heijnen, P.D., Moeton, M., van der Valk, P., Amor, S., Teunissen, C.E., van Horssen, J., Dijkstra, C.D., Macrophages in inflammatory multiple sclerosis lesions have an intermediate activation status. J. Neuroinflammation, 10, 2013, 35.
71. Christophi, G.P., Panos, M., Hudson, C.A., Christophi, R.L., Gruber, R.C., Mersich, A.T., Blystone, S.D., Jubelt, B., Massa, P.T., Macrophages of multiple sclerosis patients display deficient SHP-1 expression and enhanced inflammatory phenotype. Lab. Investig. 89 (2009), 742–759.
72. Krausgruber, T., Blazek, K., Smallie, T., Alzabin, S., Lockstone, H., Sahgal, N., Hussell, T., Feldmann, M., Udalova, I.A., IRF5 promotes inflammatory macrophage polarization and T(H)1-T(H)17 responses. Nat. Immunol. 12 (2011), 231–238.
73. Mantovani, A., Sica, A., Locati, M., Macrophage polarization comes of age. Immunity 23 (2005), 344–346.
74. Natarajan, C., Bright, J.J., Curcumin inhibits experimental allergic encephalomyelitis by blocking IL-12 signaling through Janus kinase-STAT pathway in T lymphocytes. J. Immunol. 168 (2002), 6506–6513.
75. Samoilova, E.B., Horton, J.L., Hilliard, B., Liu, T.S., Chen, Y., IL-6-deficient mice are resistant to experimental autoimmune encephalomyelitis: roles of IL-6 in the activation and differentiation of autoreactive T cells. J. Immunol. 161 (1998), 6480–6486.
76. Cua, D.J., Sherlock, J., Chen, Y., Murphy, C.A., Joyce, B., Seymore, B., Lucian, L., W. To, Kwan, S., Churakova, T., Zurawski, S., Wiekowski, M., Lira, S.A., Gorman, D., Kastelein, R.A., Sedgwick, J.D., Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature 421 (2003), 744–748.
77. Qin, H., Yeh, W.-I., De Sarno, P., Holdbrooks, A.T., Liu, Y., Muldowney, M.T., Reynolds, S.L., Yanagisawa, L.L., Fox, T.H.I., Park, K., Harrington, L.E., Raman, C., Benveniste, E.N., Signal transducer and activator of transcription-3/suppressor of cytokine signaling-3 (STAT3/SOCS3) axis in myeloid cells regulates neuroinflammation. Proc. Natl. Acad. Sci. U. S. A. 109 (2012), 5004–5009.
78. Gordon, S., Alternative activation of macrophages. Nat. Rev. Immunol. 3 (2003), 23–35.
79. Moore, K.W., de Waal Malefyt, R., Coffman, R.L., O'Garra, A., Interleukin-10 and the interleukin-10 receptor. Annu. Rev. Immunol. 19 (2001), 683–765.
80. Weber, M.S., Prod'homme, T., Youssef, S., Dunn, S.E., Rundle, C.D., Lee, L., Patarroyo, J.C., Stuve, O., Sobel, R.A., Steinman, L., Zamvil, S.S., Type II monocytes modulate T cell-mediated central nervous system autoimmune disease. Nat. Med. 13 (2007), 935–943.
81. Chitnis, T., Najafian, N., Benou, C., Salama, A.D., Grusby, M.J., Sayegh, M.H., Khoury, S.J., Effect of targeted disruption of STAT4 and STAT6 on the induction of experimental autoimmune encephalomyelitis. J. Clin. Invest. 108 (2001), 739–747.
82. Mayadas, T.N., Cullere, X., Lowell, C.A., The multifaceted functions of neutrophils. Annu. Rev. Pathol. 9 (2014), 181–218.
83. Rumble, J.M., Huber, A.K., Krishnamoorthy, G., Srinivasan, A., Giles, D.A., Zhang, X., Wang, L., Segal, B.M., Neutrophil-related factors as biomarkers in EAE and MS. J. Exp. Med. 212 (2015), 23–35.
84. Simmons, S.B., Liggitt, D., Goverman, J.M., Cytokine-regulated neutrophil recruitment is required for brain but not spinal cord inflammation during experimental autoimmune encephalomyelitis. J. Immunol. 193 (2014), 555–563.
85. Burt, R.K., Fassas, A., Snowden, J., van Laar, J.M., Kozak, T., Wulffraat, N.M., Nash, R.A., Dunbar, C.E., Arnold, R., Prentice, G., Bingham, S., Marmont, A.M., McSweeney, P.A., Collection of hematopoietic stem cells from patients with autoimmune diseases. Bone Marrow Transplant. 28 (2001), 1–12.
86. Kang, Z., Altuntas, C.Z., Gulen, M.F., Liu, C., Giltiay, N., Qin, H., Liu, L., Qian, W., Ransohoff, R.M., Bergmann, C., Stohlman, S., Tuohy, V.K., Li, X., Astrocyte-restricted ablation of interleukin-17-induced Act1-mediated signaling ameliorates autoimmune encephalomyelitis. Immunity 32 (2010), 414–425.
87. Kroenke, M.A., Carlson, T.J., Andjelkovic, A.V., Segal, B.M., IL-12- and IL-23-modulated T cells induce distinct types of EAE based on histology, CNS chemokine profile, and response to cytokine inhibition. J. Exp. Med. 205 (2008), 1535–1541.
88. Tian, S.S., Tapley, P., Sincich, C., Stein, R.B., Rosen, J., Lamb, P., Multiple signaling pathways induced by granulocyte colony-stimulating factor involving activation of JAKs, STAT5, and/or STAT3 are required for regulation of three distinct classes of immediate early genes. Blood 88 (1996), 4435–4444.
89. Nguyen-Jackson, H., Panopoulos, A.D., Zhang, H., Li, H.S., Watowich, S.S., STAT3 controls the neutrophil migratory response to CXCR2 ligands by direct activation of G-CSF-induced CXCR2 expression and via modulation of CXCR2 signal transduction. Blood 115 (2010), 3354–3363.
90. Chen, H., Assmann, J.C., Krenz, A., Rahman, M., Grimm, M., Karsten, C.M., Kohl, J., Offermanns, S., Wettschureck, N., Schwaninger, M., Hydroxycarboxylic acid receptor 2 mediates dimethyl fumarate's protective effect in EAE. J. Clin. Invest. 124 (2014), 2188–2192.
91. Christy, A.L., Walker, M.E., Hessner, M.J., Brown, M.A., Mast cell activation and neutrophil recruitment promotes early and robust inflammation in the meninges in EAE. J. Autoimmun. 42 (2013), 50–61.
92. Aube, B., Levesque, S.A., Pare, A., Chamma, E., Kebir, H., Gorina, R., Lecuyer, M.A., Alvarez, J.I., De Koninck, Y., Engelhardt, B., Prat, A., Cote, D., Lacroix, S., Neutrophils mediate blood-spinal cord barrier disruption in demyelinating neuroinflammatory diseases. J. Immunol. 193 (2014), 2438–2454.
93. Qin, H., Niyongere, S.A., Lee, S.J., Baker, B.J., Benveniste, E.N., Expression and functional significance of SOCS-1 and SOCS-3 in astrocytes. J. Immunol. 181 (2008), 31–3176.
94. Roussel, B.D., Kruppa, A.J., Miranda, E., Crowther, D.C., Lomas, D.A., Marciniak, S.J., Endoplasmic reticulum dysfunction in neurological disease. Lancet Neurol. 12 (2013), 105–118.
95. Meares, G.P., Liu, Y., Rajbhandari, R., Qin, H., Nozell, S.E., Mobley, J.A., Corbett, J.A., Benveniste, E.N., PERK dependent activation of JAK1 and STAT3 contributes to ER stress induced inflammation. Mol. Cell. Biol. 34 (2014), 3911–3925.
96. Quintana, A., Muller, M., Frausto, R.F., Ramos, R., Getts, D.R., Sanz, E., Hofer, M.J., Krauthausen, M., King, N.J., Hidalgo, J., Campbell, I.L., Site-specific production of IL-6 in the central nervous system retargets and enhances the inflammatory response in experimental autoimmune encephalomyelitis. J. Immunol. 183 (2009), 2079–2088.
97. Giralt, M., Ramos, R., Quintana, A., Ferrer, B., Erta, M., Castro-Freire, M., Comes, G., Sanz, E., Unzeta, M., Pifarre, P., Garcia, A., Campbell, I.L., Hidalgo, J., Induction of atypical EAE mediated by transgenic production of IL-6 in astrocytes in the absence of systemic IL-6. Glia 61 (2013), 587–600.
98. Ding, X., Yan, Y., Li, X., Li, K., Ciric, B., Yang, J., Zhang, Y., Wu, S., Xu, H., Chen, W., Lovett-Racke, A.E., Zhang, G.X., Rostami, A., Silencing IFN-gamma binding/signaling in astrocytes versus microglia leads to opposite effects on central nervous system autoimmunity. J. Immunol. 194 (2015), 4251–4264.
99. Anderson, M.A., Ao, Y., Sofroniew, M.V., Heterogeneity of reactive astrocytes. Neurosci. Lett. 565 (2014), 23–29.
100. Burda, J.E., Sofroniew, M.V., Reactive gliosis and the multicellular response to CNS damage and disease. Neuron 81 (2014), 229–248.
101. Sofroniew, M.V., Multiple roles for astrocytes as effectors of cytokines and inflammatory mediators. Neuroscientist 20 (2013), 160–172.
102. Qin, H., Holdbrooks, A.T., Liu, Y., Reynolds, S.L., Yanagisawa, L.L., Benveniste, E.N., SOCS3 deficiency promotes M1 macrophage polarization and inflammation. J. Immunol. 189 (2012), 3439–3448.
103. Liu, L., Belkadi, A., Darnall, L., Hu, T., Drescher, C., Cotleur, A.C., Padovani-Claudio, D., He, T., Choi, K., Lane, T.E., Miller, R.H., Ransohoff, R.M., CXCR2-positive neutrophils are essential for cuprizone-induced demyelination: relevance to multiple sclerosis. Nat. Neurosci. 13 (2010), 319–326.
104. Lampron, A., Larochelle, A., Laflamme, N., Prefontaine, P., Plante, M.M., Sanchez, M.G., Yong, V.W., Stys, P.K., Tremblay, M.E., Rivest, S., Inefficient clearance of myelin debris by microglia impairs remyelinating processes. J. Exp. Med. 212 (2015), 481–495.
105. Baxi, E.G., DeBruin, J., Tosi, D.M., Grishkan, I.V., Smith, M.D., Kirby, L.A., Strasburger, H.J., Fairchild, A.N., Calabresi, P.A., Gocke, A.R., Transfer of myelin-reactive th17 cells impairs endogenous remyelination in the central nervous system of cuprizone-fed mice. J. Neurosci. 35 (2015), 8626–8639.
106. Kannarkat, G.T., Boss, J.M., Tansey, M.G., The role of innate and adaptive immunity in Parkinson's disease. J. Parasit. Dis. 3 (2013), 493–514.
107. Samii, A., Nutt, J.G., Ransom, B.R., Parkinson's disease. Lancet 363 (2004), 1783–1793.
108. Brundin, P., Li, J.Y., Holton, J.L., Lindvall, O., Revesz, T., Research in motion: the enigma of Parkinson's disease pathology spread. Nat. Rev. Neurosci. 9 (2008), 741–745.
109. Chen, H., O'Reilly, E.J., Schwarzschild, M.A., Ascherio, A., Peripheral inflammatory biomarkers and risk of Parkinson's disease. Am. J. Epidemiol. 167 (2008), 90–95.
110. Sherer, T.B., Biomarkers for Parkinson's disease. Sci. Transl. Med. 3 (2011), 1–5.
111. Mount, M.P., Lira, A., Grimes, D., Smith, P.D., Faucher, S., Slack, R., Anisman, H., Hayley, S., Park, D.S., Involvement of interferon-gamma in microglial-mediated loss of dopaminergic neurons. J. Neurosci. 27 (2007), 3328–3337.
112. Nalls, M.A., Pankratz, N., Lill, C.M., Do, C.B., Hernandez, D.G., Saad, M., DeStefano, A.L., Kara, E., Bras, J., Sharma, M., Schulte, C., Keller, M.F., Arepalli, S., Letson, C., Edsall, C., Stefansson, H., Liu, X., Pliner, H., Lee, J.H., Cheng, R., International Parkinson's Disease Genomics, G.I. Parkinson's Study Group Parkinson's Research: The Organized, and Me, GenePd, C. NeuroGenetics Research, G. Hussman Institute of Human, I. Ashkenazi Jewish Dataset, H. Cohorts for, E. Aging Research in Genetic, C. North American Brain Expression, C. United Kingdom Brain Expression, C. Greek Parkinson's Disease, G. Alzheimer Genetic Analysis, Ikram, M.A., Ioannidis, J.P., Hadjigeorgiou, G.M., Bis, J.C., Martinez, M., Perlmutter, J.S., Goate, A., Marder, K., Fiske, B., Sutherland, M., Xiromerisiou, G., Myers, R.H., Clark, L.N., Stefansson, K., Hardy, J.A., Heutink, P., Chen, H., Wood, N.W., Houlden, H., Payami, H., Brice, A., Scott, W.K., Gasser, T., Bertram, L., Eriksson, N., Foroud, T., Singleton, A.B., Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson's disease. Nat. Genet. 46 (2014), 989–993.
113. Glass, C.K., Saijo, K., Winner, B., Marchetto, M.C., Gage, F.H., Mechanisms underlying inflammation in neurodegeneration. Cell 140 (2010), 918–934.
114. Allen Reish, H.E., Standaert, D.G., Role of alpha-synuclein in inducing innate and adaptive immunity in Parkinson disease. J. Parasit. Dis. 5 (2015), 1–19.
115. Polymeropoulos, M.H., Lavedan, C., Leroy, E., Ide, S.E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R., Stenroos, E.S., Chandrasekharappa, S., Athanassiadou, A., Papapetropoulos, T., Johnson, W.G., Lazzarini, A.M., Duvoisin, R.C., Di Iorio, G., Golbe, L.I., Nussbaum, R.L., Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 276 (1997), 2045–2047.
116. Qian, L., Flood, P.M., Microglial cells and Parkinson's disease. Immunol. Res. 41 (2008), 155–164.
117. Croisier, E., Moran, L.B., Dexter, D.T., Pearce, R.K., Graeber, M.B., Microglial inflammation in the parkinsonian substantia nigra: relationship to alpha-synuclein deposition. J. Neuroinflammation, 2, 2005, 14.
118. Couch, Y., Alvarez-Erviti, L., Sibson, N.R., Wood, M.J., Anthony, D.C., The acute inflammatory response to intranigral alpha-synuclein differs significantly from intranigral lipopolysaccharide and is exacerbated by peripheral inflammation. J. Neuroinflammation, 8, 2011, 166.
119. Qin, H., Buckley, J.A., Li, X., Liu, Y., Fox, T.H., Meares, G.P., Yu, H., Yan, Z., Harms, A.S., Li, Y., Standaert, D.G., Benveniste, E.N., Inhibition of the JAK/STAT pathway protects against α-synuclein-induced neuroinflammation and dopaminergic neurodegeneration. J. Neurosci. 36 (2016), 5144–5159.
120. Martin, J.L.S., Klucken, J., Outeiro, T.F., Nguyen, P., Keller-McGandy, C., Cantuti-Castelvetri, I., Grammatopoulos, T.N., Standaert, D.G., Hyman, B.T., McLean, P.J., Dopaminergic neuron loss and up-regulation of chaperone protein mRNA induced by targeted over-expression of alpha-synuclein in mouse substantia nigra. J. Neurochem. 100 (2007), 1449–1457.
121. Zhang, S., Wang, X.J., Tian, L.P., Pan, J., Lu, G.Q., Zhang, Y.J., Ding, J.Q., Chen, S.D., CD200-CD200R dysfunction exacerbates microglial activation and dopaminergic neurodegeneration in a rat model of Parkinson's disease. J. Neuroinflammation, 8, 2011, 154.
122. Wu, D.C., Jackson-Lewis, V., Vila, M., Tieu, K., Teismann, P., Vadseth, C., Choi, D.-K., Ischiropoulos, H., Przedborski, S., Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease. J. Neurosci. 22 (2002), 1763–1771.
123. Du, Y., Ma, Z., Lin, S., Dodel, R.C., Gao, F., Bales, K.R., Triarhou, L.C., Chernet, E., Perry, K.W., Nelson, D.L., Luecke, S., Phebus, L.A., Bymaster, F.P., Paul, S.M., Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease. Proc. Natl. Acad. Sci. U. S. A. 98 (2001), 14669–14674.
124. Schapansky, J., Nardozzi, J.D., LaVoie, M.J., The complex relationships between microglia, alpha-synuclein, and LRRK2 in Parkinson's disease. Neuroscience 302 (2015), 74–88.
125. Healy, D.G., Falchi, M., O'Sullivan, S.S., Bonifati, V., Durr, A., Bressman, S., Brice, A., Aasly, J., Zabetian, C.P., Goldwurm, S., Ferreira, J.J., Tolosa, E., Kay, D.M., Klein, C., Williams, D.R., Marras, C., Lang, A.E., Wszolek, Z.K., Berciano, J., Schapira, A.H., Lynch, T., Bhatia, K.P., Gasser, T., Lees, A.J., Wood, N.W., Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. Lancet Neurol. 7 (2008), 583–590.
126. Gardet, A., Benita, Y., Li, C., Sands, B.E., Ballester, I., Stevens, C., Korzenik, J.R., Rioux, J.D., Daly, M.J., Xavier, R.J., Podolsky, D.K., LRRK2 is involved in the IFN-gamma response and host response to pathogens. J. Immunol. 185 (2010), 5577–5585.
127. Daher, J.P., Abdelmotilib, H.A., Hu, X., Volpicelli-Daley, L.A., Moehle, M.S., Faser, K.B., Needle, E., Chen, Y., Steyn, S.J., Galatsis, P., Hirst, W.D., West, A.B., LRRK2 pharmacological inhibition abates alpha-synuclein induced neurodegeneration. J. Biol. Chem., 2015, 19433–19444.
128. Choi, I., Kim, B., Byun, J.W., Baik, S.H., Huh, Y.H., Kim, J.H., Mook-Jung, I., Song, W.K., Shin, J.H., Seo, H., Suh, Y.H., Jou, I., Park, S.M., Kang, H.C., Joe, E.H., LRRK2 G2019S mutation attenuates microglial motility by inhibiting focal adhesion kinase. Nat. Commun., 6, 2015, 8255.
129. Hamza, T.H., Zabetian, C.P., Tenesa, A., Laederach, A., Montimurro, J., Yearout, D., Kay, D.M., Doheny, K.F., Paschall, J., Pugh, E., Kusel, V.I., Collura, R., Roberts, J., Griffith, A., Samii, A., Scott, W.K., Nutt, J., Factor, S.A., Payami, H., Common genetic variation in the HLA region is associated with late-onset sporadic Parkinson's disease. Nat. Genet. 42 (2010), 781–785.
130. Raj, T., Rothamel, K., Mostafavi, S., Ye, C., Lee, M.N., Replogle, J.M., Feng, T., Lee, M., Asinovski, N., Frohlich, I., Imboywa, S., Von Korff, A., Okada, Y., Patsopoulos, N.A., Davis, S., McCabe, C., Paik, H.I., Srivastava, G.P., Raychaudhuri, S., Hafler, D.A., Koller, D., Regev, A., Hacohen, N., Mathis, D., Benoist, C., Stranger, B.E., De Jager, P.L., Polarization of the effects of autoimmune and neurodegenerative risk alleles in leukocytes. Science 344 (2014), 519–523.
131. Daher, J.P., Volpicelli-Daley, L.A., Blackburn, J.P., Moehle, M.S., West, A.B., Abrogation of alpha-synuclein-mediated dopaminergic neurodegeneration in LRRK2-deficient rats. Proc. Natl. Acad. Sci. U. S. A. 111 (2014), 9289–9294.
132. Saijo, K., Winner, B., Carson, C.T., Collier, J.G., Boyer, L., Rosenfeld, M.G., Gage, F.H., Glass, C.K., A Nurr1/CoREST pathway in microglia and astrocytes protects dopaminergic neurons from inflammation-induced death. Cell 137 (2009), 47–59.
133. Brochard, V., Combadiere, B., Prigent, A., Laouar, Y., Perrin, A., Beray-Berthat, V., Bonduelle, O., Alvarez-Fischer, D., Callebert, J., Launay, J.M., Duyckaerts, C., Flavell, R.A., Hirsch, E.C., Hunot, S., Infiltration of CD4 + lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease. J. Clin. Invest. 119 (2009), 182–192.
134. Nolan, Y.M., Sullivan, A.M., Toulouse, A., Parkinson's disease in the nuclear age of neuroinflammation. Trends Mol. Med. 19 (2013), 187–196.
135. Appel, S.H., Beers, D.R., Henkel, J.S., T cell-microglial dialogue in Parkinson's disease and amyotrophic lateral sclerosis: are we listening?. Trends Immunol. 31 (2010), 7–17.
136. O'Shea, J.J., Schwartz, D.M., Villarino, A.V., Gadina, M., McInnes, I.B., Laurence, A., The JAK-STAT pathway: impact on human disease and therapeutic intervention. Annu. Rev. Med. 66 (2015), 311–328.
137. Constantin, G., Brocke, S., Izikson, A., Laudanna, C., Butcher, E.C., Tyrphostin AG490, a tyrosine kinase inhibitor, blocks actively induced experimental autoimmune encephalomyelitis. Eur. J. Immunol. 28 (1998), 3523–3539.
138. Skarica, M., Wang, T., McCadden, E., Kardian, D., Calabresi, P.A., Small, D., Whartenby, K.A., Signal transduction inhibition of APCs diminishes th17 and Th1 responses in experimental autoimmune encephalomyelitis. J. Immunol. 182 (2009), 4192–4199.
139. Liu, Y., Holdbrooks, A.T., De Sarno, P., Rowse, A.L., Yanagisawa, L.L., McFarland, B.C., Harrington, L.E., Raman, C., Sabbaj, S., Benveniste, E.N., Qin, H., Therapeutic efficacy of suppressing the JAK/STAT pathway in multiple models of experimental autoimmune encephalomyelitis. J. Immunol. 192 (2014), 59–72.
140. Ren, Y., Lu, L., Guo, T.B., Qiu, J., Yang, Y., Liu, A., Zhang, J.Z., Novel immunomodulatory properties of berbamine through selective down-regulation of STAT4 and action of IFN-γ in experimental autoimmune encephalomyelitis. J. Immunol. 181 (2008), 1491–1498.
141. Qin, X., Guo, B.T., Wan, B., Fang, L., Lu, L., Wu, L., Zang, Y.Q., Zhang, J.Z., Regulation of Th1 and Th17 cell differentiation and amelioration of experimental autoimmune encephalomyelitis by natural product compound berberine. J. Immunol. 185 (2010), 1855–1863.
142. Zhang, J., Zeng, Y.Q., Pan, X.D., Kang, D.Y., Huang, T.W., Chen, X.C., Tripchlorolide ameliorates experimental autoimmune encephalomyelitis by down-regulating ERK1/2-NF-kappaB and JAK/STAT signaling pathways. J. Neurochem. 133 (2015), 104–112.
143. Muthian, G., Bright, J.J., Quercetin, a flavonoid phytoestrogen, ameliorates experimental allergic encephalomyelitis by blocking IL-12 signaling through JAK-STAT pathway in T lymphocyte. J. Clin. Immunol. 24 (2004), 542–552.
144. Muthian, G., Raikwar, H.P., Rajasingh, J., Bright, J.J., 1,25 dihydroxyvitamin-D3 modulates JAK-STAT pathway in IL-12/IFNgamma axis leading to Th1 response in experimental allergic encephalomyelitis. J. Neurosci. Res. 83 (2006), 1299–1309.
145. Ghoreschi, K., Bruck, J., Kellerer, C., Deng, C., Peng, H., Rothfuss, O., Hussain, R.Z., Gocke, A.R., Respa, A., Glocova, I., Valtcheva, N., Alexander, E., Feil, S., Feil, R., Schulze-Osthoff, K., Rupec, R.A., Lovett-Racke, A.E., Dringen, R., Racke, M.K., Rocken, M., Fumarates improve psoriasis and multiple sclerosis by inducing type II dendritic cells. J. Exp. Med. 208 (2011), 2291–2303.
146. Weitz-Schmidt, G., Statins as anti-inflammatory agents. Trends Pharmacol. Sci. 23 (2002), 482–486.
147. Stuve, O., Youssef, S., Steinman, L., Zamvil, S.S., Statins as potential therapeutic agents in neuroinflammatory disorders. Curr. Opin. Neurol. 16 (2003), 393–401.
148. Vollmer, T., Key, L., Durkalski, V., Tyor, W., Corboy, J., Markovic-Plese, S., Preiningerova, J., Rizzo, M., Singh, I., Oral simvastatin treatment in relapsing-remitting multiple sclerosis. Lancet 363 (2004), 1607–1608.
149. Chataway, J., Schuerer, N., Alsanousi, A., Chan, D., MacManus, D., Hunter, K., Anderson, V., Bangham, C.R., Clegg, S., Nielsen, C., Fox, N.C., Wilkie, D., Nicholas, J.M., Calder, V.L., Greenwood, J., Frost, C., Nicholas, R., Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): a randomised, placebo-controlled, phase 2 trial. Lancet 383 (2014), 2213–2221.
150. Zhang, X., Jin, J., Peng, X., Ramgolam, V.S., Markovic-Plese, S., Simvastatin inhibits IL-17 secretion by targeting multiple IL-17-regulatory cytokines and by inhibiting the expression of IL-17 transcription factor RORC in CD4 + lymphocytes. J. Immunol. 180 (2008), 6988–6996.
151. Lee, S.J., Qin, H., Benveniste, E.N., Simvastatin inhibits IFN-γ-induced CD40 gene expression by suppressing STAT-1α. J. Leukoc. Biol. 82 (2007), 436–447.